Experts at the ACCC 44th Annual Meeting & Cancer Center Business Summit identified some of the largest drivers of change and rapidly evolving initiatives in oncology care, including costs of care and precision medicine initiatives.
Where the Pathways Conversation Turns to Action
Results of a large study supported by the National Cancer Institute found that patients who survived testicular cancer are at a higher risk of developing heart disease.
A recent study examined a potential association between system-level integration and longitudinal costs of cancer care.
Socioeconomic inequalities may affect cancer-specific survival and overall survival in patients with squamous cell carcinoma of the anus.
Treatment with a BTK inhibitor has been shown to yield good depth and duration of response in patients with chronic lymphocytic leukemia, regardless of TP53 status.
Does First-Line Targeted Therapy Plus Immunotherapy Produce Durable Responses in ALK-Positive NSCLC?
A recent study assessed whether combining a targeted therapy with an immunotherapy for ALK translocation-positive advanced non-small cell lung cancer results in more durable patient responses.
Recent efforts to develop and validate a patient-reported assessment of the quality of palliative cancer care have been successful.
Long-term data show that a CAR-T therapy induces significant clinical benefit without added adverse events among patients with refractory aggressive non-Hodgkin lymphoma.
A new study suggests the strength of evidence cited by the National Comprehensive Cancer Network to support recommendations deviating from FDA-approved therapy recommendations is not robust.